HomeComparePHIOW vs PFE

PHIOW vs PFE: Dividend Comparison 2026

PHIOW yields 8620.69% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PHIOW wins by $12793007580007856.00M in total portfolio value
10 years
PHIOW
PHIOW
● Live price
8620.69%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$12793007580007856.00M
Annual income
$12,507,597,271,400,990,000,000.00
Full PHIOW calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — PHIOW vs PFE

📍 PHIOW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPHIOWPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PHIOW + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PHIOW pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHIOW
Annual income on $10K today (after 15% tax)
$732,758.62/yr
After 10yr DRIP, annual income (after tax)
$10,631,457,680,690,841,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PHIOW beats the other by $10,631,457,680,690,841,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHIOW + PFE for your $10,000?

PHIOW: 50%PFE: 50%
100% PFE50/50100% PHIOW
Portfolio after 10yr
$6396503790003928.00M
Annual income
$6,253,798,635,700,495,000,000.00/yr
Blended yield
97.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

PHIOW
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-9.1
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHIOW buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPHIOWPFE
Forward yield8620.69%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$12793007580007856.00M$49.6K
Annual income after 10y$12,507,597,271,400,990,000,000.00$26,258.71
Total dividends collected$12773964733154094.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: PHIOW vs PFE ($10,000, DRIP)

YearPHIOW PortfolioPHIOW Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$872,769$862,068.97$9,153$693.39+$863.6KPHIOW
2$71,250,409$70,316,545.72$8,593$849.25+$71.24MPHIOW
3$5,441,140,196$5,364,902,258.92$8,336$1,066.78+$5441.13MPHIOW
4$388,717,812,241$382,895,792,231.73$8,437$1,384.80+$388717.80MPHIOW
5$25,980,665,800,186$25,564,737,741,087.56$9,013$1,875.40+$25980665.79MPHIOW
6$1,624,683,420,105,904$1,596,884,107,699,705.00$10,306$2,680.72+$1624683420.10MPHIOW
7$95,065,580,496,684,460$93,327,169,237,171,150.00$12,820$4,101.38+$95065580496.67MPHIOW
8$5,205,346,525,995,166,000$5,103,626,354,863,713,000.00$17,673$6,826.70+$5205346525995.15MPHIOW
9$266,738,606,174,640,700,000$261,168,885,391,825,900,000.00$27,543$12,591.86+$266738606174640.66MPHIOW
10$12,793,007,580,007,855,000,000$12,507,597,271,400,990,000,000.00$49,560$26,258.71+$12793007580007856.00MPHIOW

PHIOW vs PFE: Complete Analysis 2026

PHIOWStock

Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. Phio Pharmaceuticals has collaboration with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Full PHIOW Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this PHIOW vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHIOW vs SCHDPHIOW vs JEPIPHIOW vs OPHIOW vs KOPHIOW vs MAINPHIOW vs JNJPHIOW vs MRKPHIOW vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.